UPDATE ON ARCHIMED ESPERION ACQUISITION

BioPharma Credit PLC

14 July 2026

 

14 July 2026

BIOPHARMA CREDIT PLC

(THE "COMPANY")

UPDATE ON ARCHIMED ESPERION ACQUISITION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, is pleased to note the announcement released 13 July 2026 by ARCHIMED ("ARCHIMED") regarding the successful closing of its acquisition of Esperion Therapeutics, Inc. On 5 May 2026 the Company announced the entering into by ARCHIMED of a definitive agreement under which funds managed by ARCHIMED would acquire Esperion in a transaction valued at up to approximately US$1.1 billion in total equity value on a fully diluted basis, assuming full achievement of certain commercial-based milestones (the "Acquisition").

In connection with the Acquisition, the Company, along with BioPharma Credit Investments V (Master) LP, provided committed financing to ARCHIMED of USD$400 million, subject to customary closing conditions for the Acquisition. The Company's allocation of such commitment was USD$120 million, which was funded at the closing of Acquisition.  Since ARCHIMED is a privately held company, further details about the senior secured loan facility are not publicly available, but the terms of the loan are generally comparable with the Company's other investments.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

[phone]

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

[phone]

[e-mail]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

END